Delving into the Latest Updates on Shenzhen Oculgen Biomedical Technology Co., Ltd. with Synapse

Overview

Tags

Eye Diseases

Congenital Disorders

Cardiovascular Diseases

Bispecific antibody

Disease domain score

A glimpse into the focused therapeutic areas

Technology Platform

Most used technologies in drug development

Targets

Most frequently developed targets

Disease Domain	Count

Endocrinology and Metabolic Disease	1

Top 5 Drug Type	Count

Bispecific antibody	1

Top 5 Target	Count

C5 x VEGFR	1

[Translation] A Phase I/II Dose-Escalation, Dose-Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics, and Preliminary Efficacy of Intravitreal OCUL101 in Patients with Neovascular Age-Related Macular Degeneration, Diabetic Macular Edema, and Geographic Atrophy Secondary to Age-Related Macular Degeneration

Ⅰ期：即研究的第1部分和第2部分，评估玻璃体内注射（IVT）OCUL101 在新生血管性年龄相关性黄斑变性（nAMD）安全性、耐受性。 Ⅱ期：即研究的第3部分，评估OCUL101 在新生血管性年龄相关性黄斑变性（nAMD）、糖尿病性黄斑水肿（DME）和继发于年龄相关性黄斑变性的地图样萎缩GA患者的代动力学（PK）、药效学（PD）和初步疗效。

[Translation]

Phase I: Part 1 and Part 2 of the study, evaluating the safety and tolerability of intravitreal injection (IVT) of OCUL101 in neovascular age-related macular degeneration (nAMD). Phase II: Part 3 of the study, evaluating the pharmacokinetic (PK), pharmacodynamics (PD) and preliminary efficacy of OCUL101 in patients with neovascular age-related macular degeneration (nAMD), diabetic macular edema (DME) and geographic atrophy secondary to age-related macular degeneration (GA).

Start Date01 Apr 2025

Sponsor / Collaborator

Shenzhen Oculgen Biomedical Technology Co., Ltd.

100 Clinical Results associated with Shenzhen Oculgen Biomedical Technology Co., Ltd.

Login to view more data

0 Patents (Medical) associated with Shenzhen Oculgen Biomedical Technology Co., Ltd.

Login to view more data

100 Deals associated with Shenzhen Oculgen Biomedical Technology Co., Ltd.

Login to view more data

100 Translational Medicine associated with Shenzhen Oculgen Biomedical Technology Co., Ltd.

Login to view more data

Corporation Tree

Boost your research with our corporation tree data.

login

or

view full example data

Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 31 May 2025

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3

Phase 2

1

Login to view more data